Migraine Newswire (Page 4)

Migraine Newswire (Page 4)

Comprehensive Real-Time News Feed for Migraine. (Page 4)

Results 61 - 80 of 1,761 in Migraine

  1. Easing Migraines with an Earplug: Interview with Cirrus Healthcare's Grant O'ConnellRead the original story w/Photo

    May 14, 2018 | Medgadget

    ... at Cirrus Healthcare , a Cold Spring Harbor, New York company, about their MigraineX earplug, how it helps mitigate migraine symptoms, and the company's other earplug products. Mohammad Saleh, Medgadget: Tell us about Cirrus Healthcare's mission and ...

    Comment?

  2. Hope for 'suicide headache' sufferersRead the original story w/Photo

    May 14, 2018 | The San Diego Union-Tribune

    While all of us have experienced the dull pain of a headache and some know the recurrent pulse and throbbing of migraine, few people can understand the severity of pain associated with cluster headache, also known as "suicide headache." Cluster headache is an extremely painful primary headache disorder characterized by recurring unilateral attacks, or attacks that occur on one side of the head.

    Comment?

  3. Antares Pharma, Inc. (ATRS) to Post FY2018 Earnings of ($0.09) Per...Read the original story w/Photo

    May 14, 2018 | AmericanBankingNews.com

    ... psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a ...

    Comment?

  4. Zosano Pharma Corp (ZSAN) Short Interest Down 43.0% in AprilRead the original story w/Photo

    May 13, 2018 | AmericanBankingNews.com

    ... a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of ...

    Comment?

  5. The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And MoreRead the original story w/Photo

    May 13, 2018 | Benzinga

    ... The FDA is set to rule on the Novartis AG (ADR) (NYSE: NVS )- Amgen, Inc. (NASDAQ: AMGN ) combine's BLA for their migraine treatment Aimovig. Xenon Pharmaceuticals Inc (NASDAQ: XENE ) is scheduled to present Phase 1 interim data for its epilepsy ...

    Comment?

  6. Jacques Gonella Sells 300,000 Shares of Antares Pharma, Inc. (ATRS) StockRead the original story w/Photo

    May 13, 2018 | IntersportsWire

    ... psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a ...

    Comment?

  7. Zosano Pharma (ZSAN) Scheduled to Post Quarterly Earnings on TuesdayRead the original story w/Photo

    May 13, 2018 | IntersportsWire

    ... a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of ...

    Comment?

  8. Brokers Issue Forecasts for Antares Pharma, Inc.'s Q2 2018 EarningsRead the original story w/Photo

    May 11, 2018 | IntersportsWire

    ... psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a ...

    Comment?

  9. Cause of vestibular migraines not knownRead the original story w/Photo

    May 10, 2018 | Brunswick News

    Dear Reader: Vestibular migraine is a relatively new diagnosis used by doctors to describe the association between vertigo and migraines. The connection itself, however, has been recognized by doctors since 1873, with the condition given multiple names, including vertiginous migraines, migrainous vertigo and migrainous vestibulopathy.

    Comment?

  10. Zosano Pharma (ZSAN) Scheduled to Post Earnings on TuesdayRead the original story w/Photo

    May 10, 2018 | AmericanBankingNews.com

    ... a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of ...

    Comment?

  11. Piper Jaffray Research Analysts Lower Earnings Estimates for Antares Pharma, Inc.Read the original story w/Photo

    May 10, 2018 | AmericanBankingNews.com

    ... psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a ...

    Comment?

  12. Antares Pharma (ATRS) PT Set at $4.00 by HC WainwrightRead the original story w/Photo

    May 8, 2018 | AmericanBankingNews.com

    ... psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a ...

    Comment?

  13. Antares Pharma (ATRS) Given a $4.00 Price Target by HC Wainwright AnalystsRead the original story w/Photo

    May 8, 2018 | IntersportsWire

    ... psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a ...

    Comment?

  14. Teva: A Better Entry Point Post-ResultsRead the original story w/Photo

    May 6, 2018 | Seeking Alpha

    ... albeit just 1 percent higher, is itself interesting as this is happening even after the launch of Teva's new migraine treatment fremanezumab has been delayed. While KA re Schultz revealed in the February 2018 earnings call that fremanezumab ...

    Comment?

  15. Zosano Pharma (ZSAN) Scheduled to Post Quarterly Earnings on MondayRead the original story w/Photo

    May 6, 2018 | Daily Political

    ... a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of ...

    Comment?

  16. Somewhat Positive Press Coverage Somewhat Unlikely to Affect Zosano Pharma (ZSAN) Stock PriceRead the original story w/Photo

    May 5, 2018 | Daily Political

    ... a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of ...

    Comment?

  17. Antares Pharma (ATRS) Upgraded at ValuEngineRead the original story w/Photo

    May 5, 2018 | IntersportsWire

    ... psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a ...

    Comment?

  18. Chronic migraine trial 'could change' woman's lifeRead the original story w/Photo

    May 4, 2018 | BBC News

    A Cardiff GP who had to quit her job because she suffered from chronic migraines is taking part in a worldwide trial in a bid to "get my life back". The World Health Organisation sees chronic migraine as one of the most disabling illnesses, comparable to dementia and active psychosis.

    Comment?

  19. IntelGenx Technologies (IGXT) Raised to "Hold" at ValuEngineRead the original story w/Photo

    May 3, 2018 | AmericanBankingNews.com

    Several other brokerages have also recently issued reports on IGXT. HC Wainwright set a $2.00 target price on shares of IntelGenx Technologies and gave the stock a "buy" rating in a report on Tuesday, April 3rd.

    Comment?

  20. Teva reports jump in first-quarter earnings, raises guidanceRead the original story w/Photo

    May 3, 2018 | Greenwich Citizen

    ... disorders like Huntington disease and tardive dyskinesia, are continuing to grow. A second proprietary drug, the migraine treatment fremanezumab, is expected to hit the U.S. market by the end of the year, after suffering delays due to manufacturing ...

    Comment?